Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 18/20 | 1.00 |
| ▸ | CA2 | P00918 | 18/20 | 1.00 |
| ▸ | CA9 | Q16790 | 14/20 | 1.00 |
| ▸ | CA4 | P22748 | 13/20 | 1.00 |
| ▸ | CA12 | O43570 | 10/20 | 0.71 |
| ▸ | CA3 | P07451 | 10/20 | 0.71 |
| ▸ | CA6 | P23280 | 10/20 | 0.71 |
| ▸ | CA5A | P35218 | 10/20 | 0.71 |
| ▸ | CA7 | P43166 | 10/20 | 0.71 |
| ▸ | CA13 | Q8N1Q1 | 10/20 | 0.71 |
| ▸ | CA14 | Q9ULX7 | 10/20 | 0.71 |
| ▸ | CA5B | Q9Y2D0 | 10/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | CA11 | O75493 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL308753 | 0.88 | CA1 (1.00) | CA1CA2CA9CA4CA12 | |
| SCHEMBL3793947 | 0.85 | CA1 (1.00) | CA1CA2CA9CA4CA12 | |
| SCHEMBL22118514 | 0.84 | CA1 (0.73) | CA1CA2CA9CA4CA12 | |
| Bromide SCHEMBL9403459 | 0.84 | CA1 (0.97) | CA1CA2CA9CA4CA12 | |
| Hydrochloric Acid SCHEMBL10446154 | 0.84 | CA1 (0.97) | CA1CA2CA9CA4CA12 | |
| SCHEMBL10958605 | 0.84 | CA1 (0.74) | CA1CA2CA9CA4CA12 | |
| SCHEMBL22118540 | 0.83 | CA1 (0.71) | CA1CA2CA9CA4CA12 | |
| SCHEMBL18475604 | 0.83 | CA1 (0.76) | CA1CA2CA9CA4CA12 | |
| SCHEMBL22118542 | 0.83 | CA1 (0.80) | CA1CA2CA9CA4CA12 | |
| SCHEMBL13740942 | 0.83 | CA2 (1.00) | CA1CA2CA9CA4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-0036351-B1 | OPHTHALMIC COMPOSITIONS OF CARBONIC ANHYDRASE INHIBITORS FOR TOPICAL APPLICATION IN THE TREATMENT OF ELEVATED INTRAOCULAR PRESSURE | MERCK & CO. INC. (US) | 1985-01-02 | — | — | EP | claimed |
| US-4483864-A | USING CARBONIC ANHYDRASE INHIBJTOR | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1984-11-20 | — | — | US | claimed |
| EP-0014642-B1 | OPHTHALMIC COMPOSITIONS COMPRISING COMBINATIONS OF CARBONIC ANHYDRASE INHIBITORS AND S-(-)-1-(TERT-BUTYLAMINO)-3-(4-MORPHOLINO-1,2,5-THIADIAZOL-3-YL)-OXY-2-PROPANOL FOR TOPICAL APPLICATION IN THE TREATMENT OF ELEVATED INTRAOCULAR PRESSURE | MERCK & CO. INC. (US) | 1984-03-21 | — | — | EP | claimed |
| US-4438123-A | Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure | MERCK & CO., INC. (US) | 1984-03-20 | — | — | US | claimed |
| EP-0036351-A2 | Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1981-09-23 | — | — | EP | claimed |
| EP-0033042-A1 | Ophthalmic inserts for lowering intraocular pressure comprising carbonic anhydrase inhibitors | MERCK & CO. INC. (US) | 1981-08-05 | — | — | EP | claimed |
| EP-0014642-A2 | Ophthalmic compositions comprising combinations of carbonic anhydrase inhibitors and S-(-)-1-(tert-butylamino)-3-(4-morpholino-1,2,5-thiadiazol-3-yl)-oxy-2-propanol for topical application in the treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1980-08-20 | — | — | EP | claimed |
| US-12378211-B2 | Carbonic anhydrase inhibitors and antibiotics against multidrug resistant bacteria | PURDUE RESEARCH FOUNDATION (US) | 2025-08-05 | — | — | US | disclosed |
| US-20220213047-A1 | CARBONIC ANHYDRASE INHIBITORS FOR TREATMENT OF NEISSERIA GONORRHOEAE INFECTION | PURDUE RESEARCH FOUNDATION (US) | 2022-07-07 | — | — | US | disclosed |
| CN-114668017-A | Application of sterilization composition containing fentrazazole-ethyl and hymexazol in reducing or preventing crop diseases | 江苏龙灯化学有限公司 | 2022-06-28 | — | — | CN | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-4438123-A | Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure | MERCK & CO., INC. (US) | 1984-03-20 | — | — | US | disclosed |
| EP-0036351-A2 | Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1981-09-23 | — | — | EP | disclosed |
| EP-0033042-A1 | Ophthalmic inserts for lowering intraocular pressure comprising carbonic anhydrase inhibitors | MERCK & CO. INC. (US) | 1981-08-05 | — | — | EP | disclosed |
| EP-0014642-A2 | Ophthalmic compositions comprising combinations of carbonic anhydrase inhibitors and S-(-)-1-(tert-butylamino)-3-(4-morpholino-1,2,5-thiadiazol-3-yl)-oxy-2-propanol for topical application in the treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1980-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378211-B2 | Carbonic anhydrase inhibitors and antibiotics against multidrug resistant bacteria | CA9, CA2, CA4 | CA1 9/4885CA2 2/4885CA9 1/4885 |
| US-20220213047-A1 | CARBONIC ANHYDRASE INHIBITORS FOR TREATMENT OF NEISSERIA GONORRHOEAE INFECTION | CA4, CA7, CA9 | CA1 11/4885CA2 6/4885CA9 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.